The FDA has recently approved pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of HER2-positive gastric or gastroesophageal junction adenocarcinoma (GEJ) in patients whose tumors express PD-L1 and a combined positive score (CPS) ≥1 based on positive results from KEYNOTE-811. ...
Esophageal
Advertisement
The safety profile of the combination was consistent with known profiles, and no new safety findings were observed.
Dr. Cytryn shares insights on the implications of recent data from the DESTINY-Gastric04 and MATTERHORN trials.
The approval is based on positive results from the phase III RATIONALE-306 study.
Patients with refractory UGI cancers who participated in phase I trials saw benefits in late-line settings.
Dr. Cytryn summarizes a trial in progress investigating a novel immunotherapy combination for gastroesophageal adenocarcinoma
The panel discusses considerations around treating peritoneal gastric cancer, including the role of HIPEC.
In part three of their discussion, the panel explores the role of ADCs in treating gastric and esophageal cancers.
The panelists discuss the impact of biomarkers on personalized gastric cancer care, including ctDNA, claudin 18.2, and PD-L1.
An expert panel of GI oncologists debates recent advancements in biomarker-driven strategies for GI cancer care.
Dr. Cytryn reviews the FDA approval of tislelizumab and shares thoughts on its clinical impact.
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.